Evaxion Reports Q3 2026 Net Loss and Strategic Pivot to Oncology

Evaxion (EVAX) has announced a strategic refocusing of its AI-Immunology platform, prioritizing oncology programs including off-the-shelf and personalized cancer vaccines. To maximize internal resources, the company will now pursue infectious disease and autoimmune assets exclusively through external partnerships. Financially, Evaxion reported a net loss of $3.5 million for the third quarter of 2026, compared to a profit in the prior-year period, largely due to the absence of out-licensing revenue from the EVX-B3 program. However, through disciplined resource allocation and equity sales via an ATM program, management has successfully extended its cash runway into late 2027. Clinical data for the EVX-01 vaccine in metastatic melanoma patients showed strong results, including an 89% target precision and a 75% objective response rate. The company expects to file a clinical trial application for its EVX-04 candidate by the end of 2026.

By Motley Fool Transcribing · Motley Fool ·

Evaxion Reports Q3 2026 Net Loss and Strategic Pivot to Oncology

Tickers: $EVAX

Topics: biotechnology cash runway clinical trial results earnings report net loss

Read the full article at Motley Fool

More World news